Gut bacteria treatment for triple-negative breast cancer
Part of Cancer, Skin clinical trials.
This trial tests whether a treatment that targets your gut bacteria (microbiome) can help fight triple-negative breast cancer before surgery. It is for people with newly diagnosed, untreated triple-negative breast cancer that has not spread far.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have triple-negative breast cancer (ER-negative, PR-negative, HER2-negative).
- Your tumor must be at least 2 cm in size (stage T2 or higher) and not have spread beyond the breast or nearby lymph nodes.
- You cannot be pregnant or breastfeeding.
- You should not be currently taking any other experimental drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving pembrolizumab (an immunotherapy drug) together with chemotherapy before surgery can help treat early-stage triple-negative breast cancer. It aims to improve outcomes by shrinking the tumor before removal.
This trial tests whether giving a targeted drug before surgery can help shrink early-stage triple-negative breast cancer tumors. It may be an option for people who have not yet had any treatment for their breast cancer.
This study is for people with early-stage triple-negative breast cancer (TNBC) that has not been treated yet. Researchers want to see if tracking tumor DNA in your blood can help guide treatment decisions. You would receive standard chemotherapy and surgery, plus give blood samples.
This trial tests a new combination of drugs given before surgery for triple-negative breast cancer. The goal is to see if it can shrink tumors and improve outcomes.
This trial tests whether using tumor “genetics” (information from your biopsy) to guide radiation planning can improve treatment for triple-negative breast cancer. It may help by aiming radiation more precisely while still using standard approaches where needed.
This study looks at how your diet and the natural bacteria in your gut (microbiome) may affect how well chemotherapy and immunotherapy work for early-stage triple-negative breast cancer. By participating, you may help doctors understand if certain gut bacteria can improve treatment outcomes.
Hear when a new Triple Negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.